USPTO Art Unit 1621 Prosecution Statistics

Art Unit Information

Art Unit: 1621
Group: 1620
Tech Center: 1600
Total Cases: 22,620
Last Active: October 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19352234SUBSTITUTED HETEROCYCLES AND USES THEREOFOctober 2025December 2025Allow200NoNo
19319360CANNABINOID ANALOGS, FORMULATIONS, AND METHODS OF USESeptember 2025January 2026Allow501YesNo
19308305TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOFAugust 2025March 2026Allow711YesNo
19290944PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOFAugust 2025January 2026Allow501YesNo
19265483CABOZANTINIB COMPOSITIONS AND METHODS OF USEJuly 2025August 2025Allow200NoNo
19238297Preparation and Application of Deuterated 4-Phenyl-4-PiperidinolsJune 2025September 2025Allow300YesNo
19224188SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTIONMay 2025January 2026Allow810NoNo
19214766METHOD FOR PREPARING CYANO SULFONYL FLUORIDE COMPOUNDSMay 2025August 2025Allow300NoNo
19207781STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABANMay 2025September 2025Allow420NoNo
19198458THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERSMay 2025February 2026Allow1010NoNo
19196683COMPOSITIONS AND METHODS FOR INHIBITION OF RASMay 2025July 2025Allow200NoNo
19189146FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOFApril 2025January 2026Allow910NoNo
19184766CABOZANTINIB COMPOSITIONS AND METHODS OF USEApril 2025October 2025Allow601NoNo
19184838CABOZANTINIB COMPOSITIONS AND METHODS OF USEApril 2025November 2025Allow701NoNo
19184689CABOZANTINIB COMPOSITIONS AND METHODS OF USEApril 2025December 2025Allow801NoNo
191774103-PHENYLPROPYLAMINE DERIVATIVEApril 2025December 2025Allow810NoNo
19079211HETEROCYCLIC COMPOUND AND USE THEREOFMarch 2025July 2025Allow410YesNo
19079172HETEROCYCLIC COMPOUND AND USE THEREOFMarch 2025July 2025Allow410YesNo
19054180GLP-1R AGONIST COMPOUND AND USE THEREOFFebruary 2025June 2025Allow410YesNo
19053093METHOD OF CONVERTING MITRAGYNINE TO 7-HYDROXYMITRAGYNINEFebruary 2025August 2025Allow600NoNo
19034407SUBSTITUTED DERIVATIVES OF ISOINDOLESJanuary 2025September 2025Allow821YesNo
19029638Compounds and Their Use for Treatment of HemoglobinopathiesJanuary 2025July 2025Allow611NoNo
19023391CALCIUM-BASED METAL-ORGANIC FRAMEWORK MATERIAL, METHOD FOR MAKING THE SAME, AND USE IN CARBON DIOXIDE CAPTUREJanuary 2025December 2025Allow1101YesNo
19020085INHIBITORS OF KIF18A AND USES THEREOFJanuary 2025June 2025Allow501NoNo
18980700THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAFDecember 2024June 2025Allow710NoNo
18977370SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTIONDecember 2024April 2025Allow410NoNo
18971536NOVEL DRP-1 INHIBITORS AS THERAPEUTIC AGENTSDecember 2024August 2025Allow811NoNo
18968101SUBSTITUTED PHENYL OXAZOLONE COMPOUNDSDecember 2024April 2025Allow510NoNo
18709340FLUORINE-CONTAINING PYRIMIDINE COMPOUNDS, HARMFUL FUNGUS CONTROL AGENT, AND METHOD FOR PRODUCING FLUORINE-CONTAINING PYRIMIDINE COMPOUNDSDecember 2024October 2025Allow1710NoNo
18955583Small Molecule Degraders and Fluorescent Probes of PXRNovember 2024November 2025Allow1121NoNo
18951509PLEUROMUTILIN ONIUM SALT DERIVATIVE CONTAINING A 3H-IMIDAZO[4,5-C]PYRIDINE SIDE CHAIN, AND A PREPARATION METHOD AND APPLICATION THEREOFNovember 2024January 2025Allow210NoNo
18946234FORMULATION PRODUCTION PROCESSNovember 2024June 2025Allow720YesNo
18943165NASAL COMPOSITIONS COMPRISING ALCAFTADINENovember 2024August 2025Abandon910NoNo
18943124NASAL COMPOSITIONS COMPRISING ALCAFTADINENovember 2024August 2025Abandon910NoNo
18943269NASAL COMPOSITIONS COMPRISING ALCAFTADINENovember 2024September 2025Abandon1020NoNo
18938926CABOZANTINIB COMPOSITIONS AND METHODS OF USENovember 2024May 2025Allow611YesNo
18927508Compositions, Systems, and Methods for Modulating a Target GeneOctober 2024January 2026Allow1521YesNo
18914691ARYL-1,2,3-TRIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR TREATMENT OF BREAST CANCEROctober 2024January 2025Allow310NoNo
18854563RUTHENIUM PRECURSOR COMPOSITION, PREPARATION METHOD THEREFOR, AND FORMATION METHOD FOR RUTHENIUM-CONTAINING FILM USING SAMEOctober 2024February 2025Allow400NoNo
18907296TOPICAL OCULAR DELIVERY OF CROMAKALIMOctober 2024January 2026Allow1620NoNo
18907300TOPICAL OCULAR DELIVERY OF CROMAKALIMOctober 2024January 2026Allow1620YesNo
18890416COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONSSeptember 2024September 2025Abandon1220NoNo
18884965GLP-1R Agonist and Therapeutic Method ThereofSeptember 2024November 2024Allow200NoNo
18823214PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFORSeptember 2024March 2025Allow601NoNo
18812060TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCERAugust 2024December 2024Allow400YesNo
18805490COMPOUNDS AS INHIBITORS OF AXLAugust 2024September 2024Allow100NoNo
18792976NATURAL AND SYNTHETIC CANNABINOIDS AS FLUORESCENT TAGS; COMPOSITIONS, METHODS, AND APPLICATIONSAugust 2024April 2025Allow801YesNo
18782879CRYSTALLINE FORMS OF A KRAS G12C INHIBITORJuly 2024December 2024Allow510YesNo
18771270Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives ThereofJuly 2024December 2025Abandon1711NoNo
18765867BENZOATE DERIVATIVESJuly 2024August 2025Allow1311NoNo
18764540MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USESJuly 2024May 2025Allow1101YesNo
18764277LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCERJuly 2024December 2024Allow610YesNo
18763302COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOFJuly 2024March 2025Abandon810NoNo
18763210PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORSJuly 2024September 2024Allow210NoNo
18762532HETEROCYCLIC GLP-1 AGONISTSJuly 2024August 2024Allow200NoNo
18759546cGAS ANTAGONIST COMPOUNDSJune 2024January 2026Allow1911NoNo
18756256HIV INHIBITOR COMPOUNDSJune 2024July 2025Allow1310NoNo
18755447AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCERJune 2024December 2025Allow1811NoNo
18755058PCNA INHIBITORSJune 2024July 2025Allow1210NoNo
18753342Metal Complexes, Methods, and Uses ThereofJune 2024January 2026Allow1821YesNo
18754044MULTIPLE MYELOMA TREATMENTJune 2024March 2026Allow2120NoNo
18754049NONIONIC POLYETHER SURFACTANTSJune 2024June 2025Allow1110NoNo
18745423Bcl-2 InhibitorsJune 2024January 2026Allow1910NoNo
18741170FLUOROLACTONE AND METHOD FOR PRODUCING SAMEJune 2024November 2025Allow1720YesNo
187348992-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEADJune 2024October 2025Allow1711NoNo
18731285HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOFJune 2024September 2025Allow1610NoNo
18676679POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTSMay 2024January 2025Allow821YesNo
18713225Acetoacetate Based KetalsMay 2024January 2026Abandon1920YesNo
18670566METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTSMay 2024January 2025Allow820YesNo
18669184TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOFMay 2024June 2025Abandon1310NoNo
18667468COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB1 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING DISEASES AND DISORDERS CHARACTERIZED BY ABNORMAL CELLULAR ACCUMULATION OF SPHINGOLIPIDS SUCH AS SPHINGOMYELINMay 2024August 2025Allow1511NoNo
18664689METHOD OF CONVERTING MITRAGYNINE TO 7-HYDROXYMITRAGYNINEMay 2024July 2025Allow1430YesNo
18663952PRMT5 INHIBITORS AND USES THEREOFMay 2024February 2025Allow911NoNo
18660578PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTIONMay 2024July 2025Allow1411NoNo
18659715Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune DisordersMay 2024April 2025Allow1101YesNo
18657306DIMETHYLTRYPTAMINE ANALOGUES AS NITRIC OXIDE DELIVERY DRUGSMay 2024December 2025Allow1910YesNo
18655883DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEMMay 2024December 2025Allow2010NoNo
18655511SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCERMay 2024August 2025Abandon1601NoNo
18655062THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERSMay 2024March 2025Allow1011YesNo
18706706METHODS FOR PREPARING DIHYDROXYAMMONIUM 5,5'-BISTETRAZOLE-1,1'DIOLATEMay 2024January 2025Allow910NoNo
18650914LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYEApril 2024July 2025Allow1531YesNo
18651214FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOFApril 2024March 2025Allow1111NoNo
18648027Combination Therapy for Use in Treating Retroviral InfectionsApril 2024November 2025Abandon1910NoNo
18646687THIOAMIDE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOFApril 2024October 2024Allow610NoNo
18644945TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORSApril 2024May 2025Allow1300NoNo
18645315GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOFApril 2024July 2024Allow300YesNo
18643710COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERSApril 2024August 2025Allow1611NoNo
18643330PEPTOID-BASED INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE (PRMT) FAMILYApril 2024April 2025Allow1211NoNo
18643948METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONESApril 2024February 2026Allow2211NoNo
18641912FUSED TRI-CYCLIC COMPOUND AS A PDE3/PDE4 DUAL INHIBITORApril 2024February 2026Allow2110YesNo
187024855 ALPHA DIHYDROTESTOSTERONE FORMULATIONS AND ASSOCIATED METHODS OF USE AND TREATMENTApril 2024March 2025Allow1130YesNo
18638097COMPOSITION CONTAINING LAMOTRIGINE, AND PREPARATION METHOD AND USE THEREOFApril 2024September 2025Allow1731YesNo
18636653SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOFApril 2024November 2025Abandon1901NoNo
18636731AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORSApril 2024February 2025Allow1000NoNo
18636240BUPROPION AS A MODULATOR OF DRUG ACTIVITYApril 2024November 2025Allow1910NoNo
18635402INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7)April 2024May 2025Abandon1310NoNo
18634599IMIDAZOTRIAZINE THIOBENZAMIDE DERIVATIVE, AND PREPARATION METHOD AND APPLICATION THEREOFApril 2024November 2024Allow710NoNo
18631725CompoundsApril 2024September 2025Abandon1701NoNo
18630760MACROCYCLIC COMPOUNDS AND USES THEREOFApril 2024December 2025Allow2010NoNo
18630017Fluorogenic Probe Using a Mislow-Evans Rearrangement for Real-Time Imaging of Hydrogen PeroxideApril 2024October 2025Allow1821NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1621.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
222
Examiner Affirmed
159
(71.6%)
Examiner Reversed
63
(28.4%)
Reversal Percentile
28.9%
Lower than average

What This Means

With a 28.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1321
Allowed After Appeal Filing
426
(32.2%)
Not Allowed After Appeal Filing
895
(67.8%)
Filing Benefit Percentile
50.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 32.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1621 - Prosecution Statistics Summary

Executive Summary

Art Unit 1621 is part of Group 1620 in Technology Center 1600. This art unit has examined 22,620 patent applications in our dataset, with an overall allowance rate of 72.9%. Applications typically reach final disposition in approximately 25 months.

Comparative Analysis

Art Unit 1621's allowance rate of 72.9% places it in the 38% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1621 receive an average of 1.42 office actions before reaching final disposition (in the 17% percentile). The median prosecution time is 25 months (in the 76% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.